Transcriptional Regulation of Antiviral Interferon-Stimulated Genes

Trends in Microbiology

Volumn 25, Issue 7, 2017, Pages 573-584

  Wang, Wenshi ^a   Xu, Lei ^a   Su, Junhong ^b   Peppelenbosch, Maikel P ^a   Pan, Qiuwei ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

IFN; ISG; transcription

Indexed keywords

CRK LIKE PROTEIN; INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 1; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RAC1 PROTEIN; RETINOIC ACID; STAT5 PROTEIN; TUMOR NECROSIS FACTOR; ANTIVIRUS AGENT;

AUTOIMMUNE DISEASE; ENZYME ACTIVITY; GENE; GENE PRODUCT; HOST RESISTANCE; HUMAN; INTERFERON-STIMULATED GENE; MICROBIAL ACTIVITY; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW; TRANSCRIPTION REGULATION; VIRUS CELL INTERACTION; VIRUS INFECTION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNITY; IMMUNOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY; INTERFERONS; JANUS KINASES; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 85010867865     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2017.01.001     Document Type: Review

References (129)

1. Wu, J., Chen, Z.J., Innate immune sensing and signaling of cytosolic nucleic acids. Annu. Rev. Immunol. 32 (2014), 461–488.
2. Schneider, W.M., et al. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32 (2014), 513–545.
3. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005), 375–386.
4. Stark, G.R., Darnell, J.E. Jr, The JAK–STAT pathway at twenty. Immunity 36 (2012), 503–514.
5. Krause, C.D., Pestka, S., Cut, copy, move, delete: the study of human interferon genes reveal multiple mechanisms underlying their evolution in amniotes. Cytokine 76 (2015), 480–495.
6. Kotenko, S.V., IFN-lambdas. Curr. Opin. Immunol. 23 (2011), 583–590.
7. Galani, I.E., et al. Type III interferons (IFNs): emerging master regulators of immunity. Adv. Exp. Med. Biol. 850 (2015), 1–15.
8. Tang, X., et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131 (2007), 93–105.
9. New, M., et al. HDAC inhibitor-based therapies: can we interpret the code?. Mol. Oncol. 6 (2012), 637–656.
10. Schroder, K., et al. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75 (2004), 163–189.
11. Kumar, K.G., et al. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J. Biol. Chem. 279 (2004), 46614–46620.
12. Malakhova, O.A., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 25 (2006), 2358–2367.
13. Zhang, X., et al. Human intracellular ISG15 prevents interferon-alpha/beta over-amplification and auto-inflammation. Nature 517 (2015), 89–93.
14. Fenner, J.E., et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat. Immunol. 7 (2006), 33–39.
15. Linossi, E.M., et al. Suppression of cytokine signaling: the SOCS perspective. Cytokine Growth Factor Rev. 24 (2013), 241–248.
16. Starr, R., et al. SOCS-1 binding to tyrosine 441 of IFN-gamma receptor subunit 1 contributes to the attenuation of IFN-gamma signaling in vivo. J. Immunol. 183 (2009), 4537–4544.
17. Farrar, M.A., Schreiber, R.D., The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11 (1993), 571–611.
18. Bernabei, P., et al. Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J. Leukoc. Biol. 70 (2001), 950–960.
19. Bach, E.A., et al. Ligand-induced autoregulation of IFN-gamma receptor beta chain expression in T helper cell subsets. Science 270 (1995), 1215–1218.
20. Babon, J.J., et al. The molecular regulation of Janus kinase (JAK) activation. Biochem. J. 462 (2014), 1–13.
21. Steen, H.C., Gamero, A.M., STAT2 phosphorylation and signaling. JAKSTAT, 2, 2013, e25790.
22. Myers, M.P., et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J. Biol. Chem. 276 (2001), 47771–47774.
23. Irie-Sasaki, J., et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409 (2001), 349–354.
24. Yamada, T., et al. CD45 controls interleukin-4-mediated IgE class switch recombination in human B cells through its function as a Janus kinase phosphatase. J. Biol. Chem. 277 (2002), 28830–28835.
25. Simoncic, P.D., et al. The T cell protein tyrosine phosphatase is a negative regulator of janus family kinases 1 and 3. Curr. Biol. 12 (2002), 446–453.
26. Ali, S., et al. SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J. Biol. Chem. 278 (2003), 52021–52031.
27. O'Shea, J.J., et al. Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 72:Suppl. 2 (2013), 111–115.
28. Ng, S.L., et al. IkappaB kinase epsilon (IKKε) regulates the balance between type I and type II interferon responses. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 21170–21175.
29. Tenoever, B.R., et al. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315 (2007), 1274–1278.
30. Steen, H.C., et al. Identification of STAT2 serine 287 as a novel regulatory phosphorylation site in type I interferon-induced cellular responses. J. Biol. Chem. 288 (2013), 747–758.
31. Ooi, E.L., et al. Novel antiviral host factor, TNK1, regulates IFN signaling through serine phosphorylation of STAT1. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 1909–1914.
32. Jiang, L.J., et al. RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 1897–1902.
33. Hou, J., et al. Hepatic RIG-I predicts survival and interferon-alpha therapeutic response in hepatocellular carcinoma. Cancer Cell 25 (2014), 49–63.
34. Staab, J., et al. CDK8 as the STAT1 serine 727 kinase?. JAKSTAT, 2, 2013, e24275.
35. Bancerek, J., et al. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response. Immunity 38 (2013), 250–262.
36. Choudhury, G.G., A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation. J. Biol. Chem. 279 (2004), 27399–27409.
37. Nguyen, H., et al. Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J. Biol. Chem. 276 (2001), 33361–33368.
38. Uddin, S., et al. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J. Biol. Chem. 277 (2002), 14408–14416.
39. Deb, D.K., et al. Activation of protein kinase C delta by IFN-gamma. J. Immunol. 171 (2003), 267–273.
40. Ramsauer, K., et al. p38 MAPK enhances STAT1-dependent transcription independently of Ser-727 phosphorylation. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 12859–12864.
41. Branger, J., et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 101 (2003), 4446–4448.
42. Wu, T.R., et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 277 (2002), 47572–47580.
43. Xu, D., Qu, C.K., Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 13 (2008), 4925–4932.
44. ten Hoeve, J., et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell. Biol. 22 (2002), 5662–5668.
45. David, M., et al. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15 (1995), 7050–7058.
46. He, R.J., et al. Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol. Sin. 35 (2014), 1227–1246.
47. Ungureanu, D., et al. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood 106 (2005), 224–226.
48. Qureshi, S.A., et al. Tyrosine-phosphorylated Stat1 and Stat2 plus a 48-kDa protein all contact DNA in forming interferon-stimulated-gene factor 3. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 3829–3833.
49. John, J., et al. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol. Cell. Biol. 11 (1991), 4189–4195.
50. Kimura, T., et al. Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1 (1996), 115–124.
51. Levy, D.E., et al. Synergistic interaction between interferon-alpha and interferon-gamma through induced synthesis of one subunit of the transcription factor ISGF3. EMBO J. 9 (1990), 1105–1111.
52. Bell, O., et al. Determinants and dynamics of genome accessibility. Nat. Rev. Genet. 12 (2011), 554–564.
53. Cui, K., et al. The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming. Mol. Cell. Biol. 24 (2004), 4476–4486.
54. Yan, Z., et al. PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. Genes Dev. 19 (2005), 1662–1667.
55. Huang, M., et al. Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat. Cell. Biol. 4 (2002), 774–781.
56. Ni, Z., et al. Apical role for BRG1 in cytokine-induced promoter assembly. Proc. Natl. Acad. Sci. U. S. A. 102 (2005), 14611–14616.
57. Bhattacharya, S., et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 383 (1996), 344–347.
58. Paulson, M., et al. IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat. Cell. Biol. 4 (2002), 140–147.
59. Shakespear, M.R., et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol. 32 (2011), 335–343.
60. Chang, H.M., et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 9578–9583.
61. Gao, B., et al. Inhibition of histone deacetylase activity suppresses IFN-gamma induction of tripartite motif 22 via CHIP-mediated proteasomal degradation of IRF-1. J. Immunol. 191 (2013), 464–471.
62. Nusinzon, I., Horvath, C.M., Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 14742–14747.
63. Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13 (2014), 673–691.
64. Klampfer, L., et al. Requirement of histone deacetylase activity for signaling by STAT1. J. Biol. Chem. 279 (2004), 30358–30368.
65. Sakamoto, S., et al. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J. Biol. Chem. 279 (2004), 40362–40367.
66. Litvak, V., et al. A FOXO3-IRF7 gene regulatory circuit limits inflammatory sequelae of antiviral responses. Nature 490 (2012), 421–425.
67. Zhang, J.J., et al. Ser727-dependent recruitment of MCM5 by Stat1alpha in IFN-gamma-induced transcriptional activation. EMBO J. 17 (1998), 6963–6971.
68. DaFonseca, C.J., et al. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-gamma. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 3034–3039.
69. Zhu, M., et al. Functional association of Nmi with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell 96 (1999), 121–130.
70. Lau, J.F., et al. Role of metazoan mediator proteins in interferon-responsive transcription. Mol. Cell. Biol. 23 (2003), 620–628.
71. Kadota, S., Nagata, K., Silencing of IFN-stimulated gene transcription is regulated by histone H1 and its chaperone TAF-I. Nucleic Acids Res. 42 (2014), 7642–7653.
72. Tahk, S., et al. Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 11643–11648.
73. Liu, B., et al. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 3203–3207.
74. Mostafavi, S., et al. Parsing the interferon transcriptional network and its disease associations. Cell 164 (2016), 564–578.
75. Morrow, A.N., et al. A novel role for IFN-stimulated gene factor 3II in IFN-gamma signaling and induction of antiviral activity in human cells. J. Immunol. 186 (2011), 1685–1693.
76. Fink, K., Grandvaux, N., STAT2 and IRF9: beyond ISGF3. JAKSTAT, 2, 2013, e27521.
77. Cheon, H., et al. IFNbeta-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage. EMBO J. 32 (2013), 2751–2763.
78. Sung, P.S., et al. Roles of unphosphorylated ISGF3 in HCV infection and interferon responsiveness. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10443–10448.
79. Fish, E.N., et al. Activation of a CrkL–stat5 signaling complex by type I interferons. J. Biol. Chem. 274 (1999), 571–573.
80. Xu, L., et al. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFN-stimulated genes. FASEB J. 30 (2016), 3352–3367.
81. Harada, H., et al. Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. Mol. Cell. Biol. 14 (1994), 1500–1509.
82. Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14 (2014), 36–49.
83. Grandvaux, N., et al. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J. Virol. 76 (2002), 5532–5539.
84. Collins, S.E., et al. Innate cellular response to virus particle entry requires IRF3 but not virus replication. J. Virol. 78 (2004), 1706–1717.
85. Bartee, E., et al. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J. Virol. 83 (2009), 498–511.
86. Wang, W., et al. Convergent transcription of interferon-stimulated genes by TNF-alpha and IFN-alpha augments antiviral activity against HCV and HEV. Sci. Rep., 6, 2016, 25482.
87. Mestan, J., et al. Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2′,5′-adenylate synthetase. J. Gen. Virol. 69 (1988), 3113–3120.
88. Lee, J., et al. TNF-alpha induced by hepatitis C virus via TLR7 and TLR8 in hepatocytes supports interferon signaling via an autocrine mechanism. PLoS Pathog., 11, 2015, e1004937.
89. Ruby, J., et al. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J. Exp. Med. 186 (1997), 1591–1596.
90. Seo, S.H., Webster, R.G., Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. 76 (2002), 1071–1076.
91. Mestan, J., et al. Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 323 (1986), 816–819.
92. Uddin, S., et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J. Biol. Chem. 275 (2000), 27634–27640.
93. Li, Y., et al. Activation of mitogen-activated protein kinase kinase (MKK) 3 and MKK6 by type I interferons. J. Biol. Chem. 280 (2005), 10001–10010.
94. Wu, T., et al. Interferon-gamma induces the synthesis and activation of cytosolic phospholipase A2. J. Clin. Invest. 93 (1994), 571–577.
95. Peppelenbosch, M.P., Rac mediates growth factor-induced arachidonic acid release. Cell 81 (1995), 849–856.
96. Young, P.R., Perspective on the discovery and scientific impact of p38 MAP kinase. J. Biomol. Screen. 18 (2013), 1156–1163.
97. Li, Y., et al. Role of p38alpha Map kinase in type I interferon signaling. J. Biol. Chem. 279 (2004), 970–979.
98. Uddin, S., et al. Activation of the p38 mitogen-activated protein kinase by type I interferons. J. Biol. Chem. 274 (1999), 30127–30131.
99. Lee, Y.B., et al. p38 map kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine 12 (2000), 874–880.
100. Hu, J., et al. ERK1 and ERK2 activate CCAAAT/enhancer-binding protein-beta-dependent gene transcription in response to interferon-gamma. J. Biol. Chem. 276 (2001), 287–297.
101. Lucas-Hourani, M., Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog., 9, 2013, e1003678.
102. Pan, Q., et al. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C virus infection in vitro and in vivo. Hepatology 55 (2012), 1673–1683.
103. Chung, D.H., et al. Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state. Antimicrob. Agents Chemother. 60 (2016), 4552–4562.
104. Wang, Y., et al. Cross talk between nucleotide synthesis pathways with cellular immunity in constraining hepatitis E virus replication. Antimicrob. Agents Chemother. 60 (2016), 2834–2848.
105. Testoni, B., et al. Ribavirin restores IFNalpha responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut 65 (2016), 672–682.
106. Neuzil, K.M., et al. Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections. Antimicrob. Agents Chemother. 39 (1995), 1191–1193.
107. Bocher, W.O., et al. All-trans retinoic acid for treatment of chronic hepatitis C. Liver Int. 28 (2008), 347–354.
108. Cho, N.E., et al. Retinoid regulation of antiviral innate immunity in hepatocytes. Hepatology 63 (2016), 1783–1795.
109. Bitetto, D., et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology 57 (2013), 925–933.
110. Debing, Y., Neyts, J., Antiviral strategies for hepatitis E virus. Antiviral Res. 102 (2014), 106–118.
111. Loutfy, M.R., et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290 (2003), 3222–3228.
112. Lasfar, A., et al. IFN-lambda therapy: current status and future perspectives. Drug Discov. Today 21 (2016), 167–171.
113. Miller, C.H., et al. Clinical use of interferon-gamma. Ann. N. Y. Acad. Sci. 1182 (2009), 69–79.
114. Lau, J.Y., et al. A randomised controlled trial of recombinant interferon-gamma in Chinese patients with chronic hepatitis B virus infection. J. Med. Virol. 34 (1991), 184–187.
115. Muir, A.J., et al. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J. Viral. Hepat. 13 (2006), 322–328.
116. Chan, H.L., et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). J. Hepatol. 64 (2016), 1011–1019.
117. Muir, A.J., et al. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J. Hepatol. 61 (2014), 1238–1246.
118. Hernandez, P.P., et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat. Immunol. 16 (2015), 698–707.
119. Pott, J., et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 7944–7949.
120. Schoggins, J.W., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472 (2011), 481–485.
121. Asselah, T., et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57 (2008), 516–524.
122. Dill, M.T., et al. Interferon-gamma-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 143 (2012), 777–786.
123. Crow, Y.J., Manel, N., Aicardi-Goutières syndrome and the type I interferonopathies. Nat. Rev. Immunol. 15 (2015), 429–440.
124. Bennett, L., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003), 711–723.
125. Mandl, J.N., et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14 (2008), 1077–1087.
126. Mullen, L.M., et al. Pattern recognition receptors as potential therapeutic targets in inflammatory rheumatic disease. Arthritis Res. Ther., 17, 2015, 122.
127. Kaplan, D.H., et al. Identification of an interferon-gamma receptor alpha chain sequence required for JAK-1 binding. J. Biol. Chem. 271 (1996), 9–12.
128. Qing, Y., et al. Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J. Biol. Chem. 280 (2005), 1849–1853.
129. Sadzak, I., et al. Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 8944–8949.